Literature DB >> 12477418

Selection of influenza vaccine strains and developing pandemic vaccines.

J M Wood1.   

Abstract

The WHO Influenza Surveillance Programme has recently celebrated 50 years of success. The programme provides representative influenza viruses for antigenic and genetic analysis and from this information, the WHO is able to make recommendations on vaccine composition. The WHO has also a key important role to play in detecting new influenza pandemic viruses and advising on suitable vaccine strains and their use. Experience in developing vaccines for pandemics or pandemic alerts in the past, has informed us that there are considerable problems to solve, not least of which is the fact that the conventional vaccines used throughout the world are unlikely to be effective in the face of a pandemic. Different strategies need developing and testing, so that we are adequately prepared.

Mesh:

Substances:

Year:  2002        PMID: 12477418     DOI: 10.1016/s0264-410x(02)00509-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

Review 1.  Structural basis of influenza virus neutralization.

Authors:  Thomas Han; Wayne A Marasco
Journal:  Ann N Y Acad Sci       Date:  2011-01-11       Impact factor: 5.691

2.  Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.

Authors:  Xiangjie Sun; Jessica A Belser; Joanna A Pulit-Penaloza; Hannah M Creager; Zhu Guo; Stacie N Jefferson; Feng Liu; Ian A York; James Stevens; Taronna R Maines; Daniel B Jernigan; Jacqueline M Katz; Min Z Levine; Terrence M Tumpey
Journal:  Virology       Date:  2017-05-26       Impact factor: 3.616

3.  Functional antagonism of chemokine receptor CCR1 reduces mortality in acute pneumovirus infection in vivo.

Authors:  Cynthia A Bonville; Vincent K Lau; Jordana M DeLeon; Ji-Liang Gao; Andrew J Easton; Helene F Rosenberg; Joseph B Domachowske
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

4.  Direct ex vivo analyses of HLA-DR1 transgenic mice reveal an exceptionally broad pattern of immunodominance in the primary HLA-DR1-restricted CD4 T-cell response to influenza virus hemagglutinin.

Authors:  Katherine A Richards; Francisco A Chaves; Frederick R Krafcik; David J Topham; Christopher A Lazarski; Andrea J Sant
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

5.  CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets.

Authors:  Cyril Jean-Marie Martel; Else Marie Agger; Julie Juul Poulsen; Trine Hammer Jensen; Lars Andresen; Dennis Christensen; Lars Peter Nielsen; Merete Blixenkrone-Møller; Peter Andersen; Bent Aasted
Journal:  PLoS One       Date:  2011-08-05       Impact factor: 3.240

6.  Towards universal influenza vaccines?

Authors:  Ab Osterhaus; Ron Fouchier; Guus Rimmelzwaan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-10-12       Impact factor: 6.237

Review 7.  Prospects of HA-based universal influenza vaccine.

Authors:  Anwar M Hashem
Journal:  Biomed Res Int       Date:  2015-02-15       Impact factor: 3.411

8.  Safety, humoral and cell mediated immune responses to two formulations of an inactivated, split-virion influenza A/H5N1 vaccine in children.

Authors:  Tawee Chotpitayasunondh; Usa Thisyakorn; Chitsanu Pancharoen; Stephanie Pepin; Nolwenn Nougarede
Journal:  PLoS One       Date:  2008-12-29       Impact factor: 3.240

Review 9.  Biosafety risk assessment for production of candidate vaccine viruses to protect humans from zoonotic highly pathogenic avian influenza viruses.

Authors:  Li-Mei Chen; Ruben O Donis; David L Suarez; David E Wentworth; Richard Webby; Othmar G Engelhardt; David E Swayne
Journal:  Influenza Other Respir Viruses       Date:  2019-10-28       Impact factor: 4.380

10.  Viral vaccine meeting held in Barcelona, October 25-28, 2003.

Authors:  A C M Boon; S Plotkin; G F Rimmelzwaan; A D M E Osterhaus
Journal:  Vaccine       Date:  2004-03-29       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.